J Biomed Transl Res.  2023 Sep;24(3):83-92. 10.12729/jbtr.2023.24.3.83.

Assessment of single oral dose toxicity of collagen peptide from skate (Raja kenojei) skin

Affiliations
  • 1Health Care Institute, Korea Testing and Research Institute, Hwasun 58141, Korea
  • 2College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, Gwangju 61186, Korea
  • 3Yeongsan Skate Co., Ltd., Naju 58266, Korea

Abstract

Collagen peptides have garnered significant attention as functional foods across multiple fields due to their capacity to regulate physiological and hormonal processes, offering nu-merous advantages. However, despite their broad range of applications, comprehensive research on the potential toxicity of these substances remains lacking. Therefore, this study sought to assess the acute oral toxicity of a collagen peptide derived from skate (Raja kenojei) skin (CPSS) in both rats and dogs. In the rat model, CPSS was orally administered at doses of 300 and 2,000 mg/kg to Sprague-Dawley rats. An escalating single-dose oral toxicity assessment at doses of 500, 1,000, and 2,000 mg/kg was carried out in beagle dogs with 3-day intervals between doses. Throughout the 14-day post-administration assessment period, clinical signs, mortality rates, changes in body weight, and necropsy observations were closely monitored. After oral administration, no signs of toxicity associated with CPSS were observed in either rats or dogs. Therefore, the oral LD50 (approximate lethal dose for 50% mortality) for CPSS in rats was determined to exceed 5,000 mg/kg, and the maximum toler- ated dose for dogs was estimated to be above 2,000 mg/kg. Consequently, this study offers safety data on the use of CPSS in functional foods and medicinal applications.

Keyword

collagen; toxicity test; skate; lethal dose 50 (LD50); maximum tolerated dose
Full Text Links
  • JBTR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr